Piper Sandler analyst Jessica Tassan raised the firm’s price target on Evolent Health to $51 from $44 and keeps an Overweight rating on the shares. The analyst assume the Magellan Specialty Health acquisition closes in the first half of 2023 and introduced pro forma estimates. She views Evolent’s acquisitions as "transformational."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVH:
